Safety and efficacy of strontium-89 for prostate cancer with painful bone metastases in Japanese patients

Safety and efficacy of strontium-89 for prostate cancer with painful bone metastases in Japanese patients - Feasibility of strontium-89 for prostate cancer with painful bone metastases in Japanese patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004517

Enrollment

100

Registered

2010-11-08

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

castration-resistant prostate cancer patients with painful bone metastases

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: (1) Prostatic cancer with positive bone scintigraphy findings and painful bone metastasis (2) No prior treatment with Sr-89 (3) Expected life span of more than 3 months (4) Adequate hematologic functions *In patients receiving chemotherapy, investigators must confirm a tendency to improvement in the laboratory value from the lowest level after treatment. (5) Submission of informed consent for participation in this study after a full explanation of the study.

Exclusion criteria

Exclusion criteria: (1) Severe myelosuppression *Severe myelosuppression should be measured by hematologic functions (platelets < 50,000/mm3, WBC < 2,000/mm3, neutrophils < 1,000/mm3, Hb < 8.0/dL). (2) Diagnosis of disseminated intravascular coagulation syndrome (DIC) (3) Severe renal dysfunction (e.g. renal failure of NCI Common Toxicity Criteria Grade 3/4)

Design outcomes

Primary

Measure	Time frame
Safety and effectivity	—

Countries

Japan

Contacts

Public ContactYasuhide Miyoshi

Yokohama City Medical Center Derpartment of Urology

miyoyasu@med.yokohama-cu.ac.jp045-261-5656

Outcome results